Small-molecule glycoprotein IIb/IIIa antagonists and bleeding risk in women: too much of a good thing?
Leopold
Jane A
JA
D000789:Angina, Unstable / Q000150:complications / Q000188:drug therapy; D001803:Blood Transfusion / Q000706:statistics & numerical data; D002543:Cerebral Hemorrhage / Q000139:chemically induced; D003404:Creatinine / Q000097:blood; D004198:Disease Susceptibility; D004305:Dose-Response Relationship, Drug; D005260:Female; D005919:Glomerular Filtration Rate; D006470:Hemorrhage / Q000139:chemically induced* / Q000209:etiology / Q000628:therapy; D006474:Hemorrhagic Disorders / Q000150:complications / Q000453:epidemiology; D006801:Humans; D007674:Kidney Diseases / Q000150:complications / Q000178:diet therapy / Q000503:physiopathology; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D016032:Randomized Controlled Trials as Topic; D012042:Registries; D012727:Sex Characteristics
D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D003404:Creatinine